London’s CoMind Raises €85M To Revolutionize Non-invasive Brain Monitoring

The latest €51 million round was led by Plural, with participation from LocalGlobe, Latitude, Octopus Ventures, Crane, Angelini Ventures, and Lord David Prior. The funds will fuel U.S. clinical trials, regulatory approvals, and manufacturing partnerships as CoMind moves toward global scale.

“James is truly a generational Founder and partnering with him and his team has been one of our great privileges as investors. We couldn’t be more excited to continue supporting them as they redefine how the brain is measured, and, ultimately, how it’s treated,” said Julia Hawkins, General Partner at LocalGlobe and Latitude, in a public statement. Hawkins previously appeared in a 2024 episode of the EU-Startups podcast, where CoMind was mentioned among her portfolio companies.

Recent sector activity includes Switzerland’s Rhovica Neuroimaging (€2.5M) for neurosurgical navigation, Spain’s Quibim (€47.9M) for imaging biomarkers, the UK’s Neu Health (€1.9M) for AI-driven neuro care and Belgium’s Koios Care (€1M) for passive monitoring via wearables.

Read Also - Certificall Raises €1M Seed To Expand In Europe

Against this backdrop CoMind’s €51M raise bringing total funding to over €85M marks one of Europe’s largest neuro-device investments this year, reflecting strong investor confidence in non-invasive brain tech and reinforcing the UK’s leadership in HealthTech innovation.

“CoMind is redefining how the brain is measured, entirely non-invasively, using breakthroughs in photonics, replacing a puncture through the skull,” added Hawkins.

Founded in 2018 by then 25-year-old James Dacombe, CoMind is redefining brain monitoring with its non-invasive technology. Its flagship device, CoMind One, uses low-power laser light to measure cerebral blood flow and intracranial pressure without drilling into the skull.

Designed for ICUs, surgical theatres, and neuro-critical settings, the device represents a breakthrough in brain health monitoring.

The leadership team includes Frank Fischer (Chair), Dr. Michael Tarnoff (former Tufts Medical Center CEO), and Professor Marc Bloom (CMO, University of Miami), with advisory input from experts at Johns Hopkins, Harvard Medical School, and the Cleveland Clinic.

Its first target market traumatic brain injury (TBI) still depends heavily on invasive monitoring. With an addressable neuro-critical care market exceeding 50 million patients annually in the US, CoMind’s technology could transform patient outcomes globally.

Just as Intuitive Surgical revolutionised robotic surgery, CoMind is positioned to make non-invasive brain monitoring the new clinical standard—building a scalable platform for AI-driven, personalised brain health.